drugset / Trial / NCT05968482

Bioavailability and Safety Study Comparing Two Dose Levels of AMZ001 and One Dose Level of Diclofenac Sodium 1% Gel in Healthy Participants

NCT05968482

Phase 1 Completed 74 enrolled Amzell
RandomizedCrossoverOpen-labelTreatment

Summary

The goal of this clinical trial is to compare drug exposure from two different products (AMZ001 and Diclofenac Sodium 1% Gel) in healthy participants on Day 7 after repeated topical administrations for 7 days. Participants will receive, in a crossover design, three different treatments * AMZ001 Low dose * AMZ001 High dose * Diclofenac Sodium 1% Gel Safety and tolerability of AMZ001 will be also investigated.

Timeline

Start
2023-07-11
Primary completion
2023-12-27
Completion
2024-12-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Diclofenac Other / unclassified 1 % Topical
Subject Diclofenac Other / unclassified 3.06 % Topical

Indications

No indication recorded.